Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 13 | 2022 | 206 | 2.520 |
Why?
|
| Laparoscopy | 12 | 2010 | 237 | 2.030 |
Why?
|
| Prostatic Neoplasms | 14 | 2021 | 778 | 1.990 |
Why?
|
| Nephrectomy | 9 | 2019 | 103 | 1.510 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2022 | 110 | 1.330 |
Why?
|
| Fluoroquinolones | 2 | 2016 | 49 | 1.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2016 | 138 | 1.050 |
Why?
|
| Penile Neoplasms | 2 | 2011 | 11 | 0.810 |
Why?
|
| Prostatectomy | 7 | 2021 | 87 | 0.760 |
Why?
|
| Allostasis | 1 | 2020 | 6 | 0.750 |
Why?
|
| Societies, Medical | 9 | 2022 | 403 | 0.710 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 43 | 0.710 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 1026 | 0.680 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2018 | 6 | 0.670 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 32 | 0.640 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 444 | 0.560 |
Why?
|
| Kidney | 5 | 2009 | 945 | 0.520 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2018 | 41 | 0.510 |
Why?
|
| Humans | 54 | 2022 | 68525 | 0.470 |
Why?
|
| Radiotherapy | 1 | 2013 | 86 | 0.450 |
Why?
|
| Ureteral Neoplasms | 4 | 2018 | 8 | 0.450 |
Why?
|
| Veterans | 1 | 2020 | 904 | 0.430 |
Why?
|
| Male | 33 | 2022 | 37281 | 0.420 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 581 | 0.410 |
Why?
|
| Penis | 1 | 2011 | 25 | 0.410 |
Why?
|
| Cryosurgery | 2 | 2010 | 53 | 0.410 |
Why?
|
| Pyelonephritis | 2 | 2022 | 17 | 0.390 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 39 | 0.390 |
Why?
|
| Robotics | 1 | 2011 | 56 | 0.390 |
Why?
|
| Prostate | 3 | 2017 | 116 | 0.380 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1070 | 0.380 |
Why?
|
| Evidence-Based Medicine | 7 | 2022 | 438 | 0.380 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 49 | 0.380 |
Why?
|
| Ureteroscopy | 2 | 2018 | 5 | 0.350 |
Why?
|
| Infusion Pumps | 1 | 2009 | 39 | 0.340 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2005 | 138 | 0.340 |
Why?
|
| Diagnostic Imaging | 3 | 2021 | 201 | 0.340 |
Why?
|
| Watchful Waiting | 3 | 2022 | 25 | 0.340 |
Why?
|
| Narcotics | 1 | 2009 | 65 | 0.340 |
Why?
|
| Anesthetics, Local | 1 | 2009 | 83 | 0.330 |
Why?
|
| Neoplasm Seeding | 1 | 2007 | 7 | 0.320 |
Why?
|
| Aged | 19 | 2020 | 14842 | 0.310 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 955 | 0.310 |
Why?
|
| Kidney Pelvis | 3 | 2004 | 12 | 0.310 |
Why?
|
| Length of Stay | 2 | 2009 | 780 | 0.310 |
Why?
|
| Cystectomy | 2 | 2004 | 13 | 0.300 |
Why?
|
| Operating Rooms | 3 | 2022 | 108 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 624 | 0.280 |
Why?
|
| Middle Aged | 15 | 2020 | 21119 | 0.280 |
Why?
|
| United States | 13 | 2022 | 7335 | 0.270 |
Why?
|
| Urothelium | 3 | 2018 | 22 | 0.270 |
Why?
|
| Cholecalciferol | 3 | 2016 | 143 | 0.230 |
Why?
|
| Radiology | 2 | 2021 | 97 | 0.230 |
Why?
|
| Ultrasonography | 4 | 2022 | 453 | 0.230 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 26 | 0.220 |
Why?
|
| Polymyositis | 1 | 2002 | 5 | 0.220 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2002 | 9 | 0.220 |
Why?
|
| Hematuria | 3 | 2020 | 24 | 0.220 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 71 | 0.210 |
Why?
|
| Patient Portals | 1 | 2021 | 12 | 0.200 |
Why?
|
| Treatment Failure | 2 | 2013 | 216 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2022 | 2222 | 0.200 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 799 | 0.200 |
Why?
|
| Muscles | 1 | 2001 | 158 | 0.190 |
Why?
|
| Renal Veins | 1 | 2000 | 18 | 0.190 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2000 | 28 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 121 | 0.180 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 475 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4843 | 0.180 |
Why?
|
| Risk Factors | 7 | 2020 | 5719 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Biopsy | 2 | 2018 | 539 | 0.170 |
Why?
|
| Minority Groups | 1 | 2020 | 196 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 168 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 114 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.160 |
Why?
|
| Hypertension, Renovascular | 1 | 2017 | 47 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7264 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2022 | 3702 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 170 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 951 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 369 | 0.150 |
Why?
|
| Carcinoma | 2 | 2012 | 215 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2018 | 212 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 848 | 0.140 |
Why?
|
| Radiography | 2 | 2012 | 572 | 0.140 |
Why?
|
| Systems Analysis | 1 | 2016 | 33 | 0.140 |
Why?
|
| Prostatitis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Dietary Supplements | 3 | 2016 | 331 | 0.140 |
Why?
|
| Contrast Media | 1 | 2019 | 594 | 0.140 |
Why?
|
| Transcriptome | 1 | 2016 | 164 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 772 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 320 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1593 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 657 | 0.120 |
Why?
|
| Female | 12 | 2022 | 38015 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 508 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2264 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 14 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2020 | 307 | 0.120 |
Why?
|
| Prognosis | 3 | 2017 | 2093 | 0.110 |
Why?
|
| Quality of Life | 2 | 2020 | 1515 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 627 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2013 | 82 | 0.110 |
Why?
|
| Adult | 7 | 2020 | 21375 | 0.110 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2011 | 20 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 91 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 274 | 0.100 |
Why?
|
| Ureteral Obstruction | 2 | 2000 | 25 | 0.100 |
Why?
|
| Urinary Diversion | 2 | 2000 | 16 | 0.090 |
Why?
|
| Nephrons | 1 | 2009 | 17 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2011 | 200 | 0.090 |
Why?
|
| Endoscopy | 2 | 2004 | 464 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 85 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2020 | 2004 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 2356 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 110 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 1425 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2006 | 49 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 144 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2005 | 46 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 3256 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.060 |
Why?
|
| Living Donors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 2 | 2000 | 47 | 0.060 |
Why?
|
| Forecasting | 1 | 2005 | 277 | 0.060 |
Why?
|
| Kidney Calices | 1 | 2003 | 2 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2011 | 1615 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 2003 | 19 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2013 | 7028 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2323 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 299 | 0.050 |
Why?
|
| Polyps | 1 | 2000 | 12 | 0.050 |
Why?
|
| Ureter | 1 | 2000 | 16 | 0.050 |
Why?
|
| Diathermy | 1 | 2000 | 5 | 0.050 |
Why?
|
| Infertility, Male | 1 | 2000 | 35 | 0.050 |
Why?
|
| Morbidity | 1 | 2001 | 130 | 0.050 |
Why?
|
| Efficiency | 1 | 2021 | 49 | 0.050 |
Why?
|
| Ultrasonic Therapy | 1 | 2000 | 19 | 0.050 |
Why?
|
| Photons | 1 | 2000 | 32 | 0.050 |
Why?
|
| Microwaves | 1 | 2000 | 31 | 0.050 |
Why?
|
| Workflow | 1 | 2021 | 100 | 0.050 |
Why?
|
| Laser Therapy | 1 | 2000 | 54 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1753 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 129 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 38 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 81 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 202 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 191 | 0.040 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 1 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 219 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2018 | 44 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 145 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 839 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2000 | 307 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 429 | 0.040 |
Why?
|
| Alloys | 1 | 2018 | 66 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2017 | 147 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1174 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2077 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.040 |
Why?
|
| Stents | 1 | 2000 | 657 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1139 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1465 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 592 | 0.030 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 22 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 67 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 349 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.030 |
Why?
|
| Ileum | 2 | 2000 | 28 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 447 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 285 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 1055 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 292 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 516 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1745 | 0.020 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2004 | 5 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2004 | 13 | 0.020 |
Why?
|
| Choledocholithiasis | 1 | 2004 | 14 | 0.020 |
Why?
|
| Case Management | 1 | 2004 | 46 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2004 | 164 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 100 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 4655 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 271 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 467 | 0.010 |
Why?
|
| Ohio | 1 | 2000 | 64 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 1172 | 0.010 |
Why?
|